Immunogenicity of a viral model vaccine after different inactivation procedures.

Immunogenicity of a viral model vaccine after different inactivation procedures.

Various strategies for the production of safe vaccines have been used. This study compared three different inactivation procedures, i.e. treatment with formaldehyde, beta-propiolactone or UV-light using vesicular stomatitis virus (VSV) as a model antigen. All three inactivation procedures drasticall...

Detaylı Bibliyografya
Asıl Yazarlar:	Bachmann, M, Bast, C, Hengartner, H, Zinkernagel, R
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Springer-Verlag 1994

Benzer Materyaller

Correlation of tolerogenicity of a viral antigen with its immunogenicity.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Induction of long-lived germinal centers associated with persisting antigen after viral infection.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.
Yazar:: Oxenius, A, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"?
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
Yazar:: Juan Li, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep
Yazar:: Matome Selina Matsiela, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection.
Yazar:: Oxenius, A, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®)
Yazar:: Parul Sinha, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Induction of protective cytotoxic T cells with viral proteins.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Induction of protective cytotoxic T cells with viral proteins
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Yazar:: Sitthichai Kanokudom, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

TAP1-independent loading of class I molecules by exogenous viral proteins.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Production testing of antigenicity and immunogenicity of bivalent inactivated vaccine salmonellosis vaccine
Yazar:: O. P. Boiko, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system.
Yazar:: Oxenius, A, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles
Yazar:: Tingfeng Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
Yazar:: Eddy Fadlyana, ve diğerleri
Baskı/Yayın Bilgisi: (2011-02-01)

Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.
Yazar:: Roost, H, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Immunogenicity of Concentrated and Purified Inactivated Avian Influenza Vaccine Formulation
Yazar:: A. Nazari, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
Yazar:: A.N. Mironov, ve diğerleri
Baskı/Yayın Bilgisi: (2010-07-01)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
Yazar:: A.N. Mironov, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

T cells and memory lapses - Response
Yazar:: Zinkernagel, R, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Immunogenicity of Viral Vaccines in the Italian Military
Yazar:: Claudia Ferlito, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.
Yazar:: Oxenius, A, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models
Yazar:: Ze-Jun Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
Yazar:: Maryam Keshtkar-Jahromi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
Yazar:: Auchara Tangsathapornpong, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
Yazar:: Yang Lei, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
Yazar:: Ainur Nurpeisova, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

How to Increase the Immunogenicity of SARS-COV-2 Inactivated Vaccines?
Yazar:: Yousef Khadivi
Baskı/Yayın Bilgisi: (2021-12-01)

Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice
Yazar:: Aqian Li, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Analysis of Viral and Host Factors on Immunogenicity of 2018, 2019, and 2020 Southern Hemisphere Seasonal Trivalent Inactivated Influenza Vaccine in Adults in Brazil
Yazar:: Artur Capão, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
Yazar:: Wey Wen Lim, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Immunopathology or organ-specific autoimmunity as a consequence of virus infection.
Yazar:: Aichele, P, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

EPITOPE REPETITIVENESS AS A SELF NONSELF DISCRIMINATOR FOR B-CELLS
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

Viral escape and the failure of cellular immune responses.
Yazar:: Klenerman, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Green Tea Catechin-Inactivated Viral Vaccine Platform
Yazar:: Yun H. Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2017-12-01)